Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab every 6 weeks in relapsed or refractory classical Hodgkin lymphoma or primary mediastinal large B-cell lymphoma
2024-510979-38-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBCL) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR) per Lugano Classification as Assessed by Investigator. Started May 2021; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2024-510979-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510979-38-00.